For years, global healthcare has been trying to catch up with one simple reality—patients need better, faster, and more affordable treatment. But the system hasn’t always kept pace. High-cost biologics made life-saving therapies out of reach for...

Explore the evolution of Pharma CDMOs in India and the rise of the CDMO 2.0 model in 2026. Discover key trends, market growth, biologics, digital transformation, and why India is emerging as a global hub for contract development and manufacturing.

Year-end is where most pharma companies slip. Not because of big mistakes—but small misses in tax, filings, and documentation. In 2026, with the industry growing at 9-11%, tighter compliance matters more than ever.

Walk into any urban clinic in India today and you will hear one name migrating from endocrinology journals to dinner-table conversation: semaglutide. Since the drug's Indian patent expired on March 20, 2026, generics from Dr. Reddy's, Sun Pharma...

India's pharma sector evolves with Biopharma SHAKTI Scheme, focusing on biologics, biosimilars, and advanced therapies to boost global competitiveness and healthcare.

India’s pharmaceutical industry is shaping global healthcare, and women leaders are playing a decisive role in that growth. This Women’s Day 2026 feature highlights ten influential women leading strategy, innovation, and expansion across India’s phar